Russell Investments Group
KROS icon

Russell Investments Group’s Keros Therapeutics KROS Stock Holding History

Russell Investments Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$898K Buy
81,311
+537
+0.7% +$8.29K ﹤0.01% 2272
2025
Q4 		$1.64M Sell
80,774
-12,265
-13% -$215K ﹤0.01% 1979
2025
Q3 		$1.47M Buy
93,039
+31,296
+51% +$462K ﹤0.01% 2021
2025
Q2 		$824K Buy
61,743
+53,489
+648% +$722K ﹤0.01% 2154
2025
Q1 		$84.1K Sell
8,254
-25,067
-75% -$291K ﹤0.01% 2794
2024
Q4 		$527K Sell
33,321
-68,995
-67% -$3.59M ﹤0.01% 2255
2024
Q3 		$5.94M Buy
102,316
+19,964
+24% +$986K 0.01% 1103
2024
Q2 		$3.76M Hold
82,352
– – 0.01% 1289
2024
Q1 		$5.45M Sell
82,352
-12,205
-13% -$724K 0.01% 1127
2023
Q4 		$3.76M Buy
94,557
+18,682
+25% +$586K 0.01% 1275
2023
Q3 		$2.42M Buy
75,875
+7,313
+11% +$273K ﹤0.01% 1439
2023
Q2 		$2.75M Buy
68,562
+12,976
+23% +$569K 0.01% 1381
2023
Q1 		$2.37M Buy
55,586
+14,379
+35% +$726K ﹤0.01% 1475
2022
Q4 		$1.98M Buy
41,207
+16,348
+66% +$764K ﹤0.01% 1600
2022
Q3 		$934K Buy
+24,859
New +$862K ﹤0.01% 1966

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Russell Investments Group's KROS Position: Q1 2026 in Review

Russell Investments Group increased its Keros Therapeutics (KROS) stake by 0.66% in Q1 2026, buying an estimated $8.29K and bringing the position to 81,311 shares worth $898K. The position accounts for ﹤0.01% of the portfolio, ranked #2272.

Russell Investments Group first reported a position in KROS in Q3 2022 and has held it in 15 quarters since. The position peaked at $5.94M in Q3 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Russell Investments Group held 81,311 shares of Keros Therapeutics worth $898K as of Q1 2026.
  • Russell Investments Group bought 537 Keros Therapeutics shares in Q1 2026, an estimated $8.29K.
  • Keros Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #2272 holding.
  • Russell Investments Group first reported a position in Keros Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Russell Investments Group's Keros Therapeutics position peaked at $5.94M in Q3 2024.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.